BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
NVO upcoming catalysts
Novo Nordisk A/S: 4 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (2 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 14 readout(s) and 8 FDA event(s). Subscribe to NVO (.ics).
Drugs: Semaglutide, Ziltivekimab, Tirzepatide, NNC0662-0419, UBT251, Insulin icodec, Insulin glargine, Insulin aspart
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-14 est. | P2 | Novo Nordisk A/S NVO | NCT07184632 A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity | Overweight; Obesity | active not recruiting | 224 |
| 2027-01-14 est. | P2 | Novo Nordisk A/S NVO | NCT07395687 A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity | Overweight; Obesity | recruiting | 333 |
| 2027-01-25 est. | P3 | Novo Nordisk A/S NVO | NCT07076199 A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Ins | Diabetes Mellitus, Type 1 | active not recruiting | 877 |
| 2027-01-29 est. | P3 | Novo Nordisk A/S NVO | NCT06118281 ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | Cardiovascular Risk; Acute Myocardial Infarction (AMI) | active not recruiting | 10000 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-10-23 | FDA approval | approved | NOVO NORDISK INC NVO | AWIQLI FLEXTOUCH | Approved 2026-10-23: AWIQLI FLEXTOUCH (BLA761326 SUPPL1) |
| 2026-03-26 | FDA approval | approved | NOVO NORDISK INC NVO | AWIQLI FLEXTOUCH | Approved 2026-03-26: AWIQLI FLEXTOUCH (BLA761326 ORIG2) |
| 2026-03-19 | FDA approval | approved | NOVO NVO | WEGOVY WEGOVY FLEXTOUCH WEGOVY HD | Approved 2026-03-19: WEGOVY; WEGOVY FLEXTOUCH; WEGOVY HD (NDA215256 SUPPL29) |
| 2026-02-27 | FDA approval | approved | NOVO NORDISK INC NVO | SOGROYA | Approved 2026-02-27: SOGROYA (BLA761156 SUPPL15) |
| 2026-02-27 | FDA approval | approved | NOVO NORDISK INC NVO | SOGROYA | Approved 2026-02-27: SOGROYA (BLA761156 SUPPL14) |
| 2026-02-27 | FDA approval | approved | NOVO NORDISK INC NVO | SOGROYA | Approved 2026-02-27: SOGROYA (BLA761156 SUPPL12) |
| 2025-12-22 | FDA approval | approved | NOVO NVO | WEGOVY | Approved 2025-12-22: WEGOVY (NDA218316 ORIG1) |
| 2025-11-21 | FDA approval | approved | NOVO NVO | WEGOVY WEGOVY FLEXTOUCH WEGOVY HD | Approved 2025-11-21: WEGOVY; WEGOVY FLEXTOUCH; WEGOVY HD (NDA215256 SUPPL23) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-01 est. | P3 | Novo Nordisk A/S NVO | NCT06200207 A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | Heart Failure; Systemic Inflammation | active not recruiting | 673 |
| 2026-09-03 | P3 | Novo Nordisk A/S NVO | NCT05636176 A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | Heart Failure | terminated | 4874 |
| 2026-09-01 est. | P2 | Novo Nordisk A/S NVO | NCT06717698 A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | Chronic Kidney Disease | recruiting | 465 |
| 2026-06-29 | P3 | Novo Nordisk A/S NVO | NCT07271251 A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People Wi | Type 2 Diabetes | completed | 267 |
| 2026-06-26 | P2 | Novo Nordisk A/S NVO | NCT06797869 A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy | Diabetes Mellitus, Type 2; Diabetic Peripheral Neuropathy | completed | 142 |
| 2026-06-09 | P3 | Novo Nordisk A/S NVO | NCT05021835 ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation | Cardiovascular Risk; Chronic Kidney Disease; Inflammation | completed | 6385 |
| 2026-06-02 | P3 | Novo Nordisk A/S NVO | NCT06534411 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGL | Diabetes Mellitus, Type 2 | completed | 1023 |
| 2026-04-22 | P3 | Novo Nordisk A/S NVO | NCT06388187 A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight | Obesity | completed | 300 |
| 2026-04-21 | P3 | Novo Nordisk A/S NVO | NCT05135559 A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors | Haemophilia A and B With and Without Inhibitors | active not recruiting | 153 |
| 2026-03-09 | P2 | Novo Nordisk A/S NVO | NCT05725902 Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease | Sickle Cell Disease | completed | 12 |
| 2026-03-04 | P3 | Novo Nordisk A/S NVO | NCT06221969 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With | Type 2 Diabetes | completed | 1024 |
| 2025-12-08 | P3 | Novo Nordisk A/S NVO | NCT06131437 A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight | Obesity | completed | 809 |
| 2025-11-21 | P2 | Novo Nordisk A/S NVO | NCT06409130 Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease | Alcohol-related Liver Disease | completed | 270 |
| 2025-11-19 | P3 | Novo Nordisk A/S NVO | NCT06065540 A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes T | Type 2 Diabetes Mellitus | completed | 2734 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.